EXPRESSION OF HHLA2 IN CARDIA CARCINOMA AND ITS CORRELATION WITH CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS

Xiaodong Zheng^#, Weimin Zhang^#, Guangchen Yue, Xudong Wei, Shiwei Nie^*

Department of Thoracic Surgery, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, Henan Province, China

Objective: To investigate the expression of HHLA2 in cardiac carcinoma and its correlation with clinicopathological features and patient prognosis. 

Methods: Tumour tissue from 73 patients diagnosed with cardiac cancer and operated on in our hospital between March 2017 and May 2018 and 24 adjacent normal tissues were used as the research subjects in this study. The expression level of HHLA2 in cardiac cancer and adjacent normal tissue; the relationship between HHLA2 expression level and clinicopathological features in patients with cardiac cancer; the correlation between HHLA2 expression level and prognosis in patients with cardiac cancer; and the relationship between various clinicopathological features and survival rate were all evaluated by the Cox model. 

Results: The positive expression rate of HHLA2 in cardiac cancer was 75.34% (55/73), which was significantly higher than the rate of 33.33% (8/24) in the adjacent normal tissue (P<0.05). The diameter, degree of invasion, lymph node metastasis and tumour differentiation were significantly correlated with the positive expression of HHLA2 (P<0.05). The three-year survival rate of HHLA2 positive was 70.90% (39/55), which was significantly higher than 33.33% (6/18) in patients with a negative HHLA2 expression (P<0.05). The positive expression of HHLA2, tumour diameter, degree of invasion, lymph node metastasis and tumour differentiation may all be independent risk factors affecting the survival rate of patients with cardiac cancer (P<0.05). 

Conclusion: The positive expression level of HHLA2 is closely related to clinicopathological features and patient prognosis, such as tumour diameter, degree of invasion, degree of tumour differentiation and lymph node metastasis. HHLA2 can provide an important reference value for the study of cardiac cancer and can also provide an important reference basis for clinical treatment.